Cordis gets April panel review date for carotid stent
This article was originally published in Clinica
Executive Summary
Johnson & Johnson's Cordis division appears to be maintaining its lead in the race to market in the US potentially blockbuster devices for treating patients with a dangerous buildup of plaque inside their carotid arteries that puts them at risk of a stroke.